These results suggested that CAFs could promote angiogenesis via PGF-VEGFR1 in ICC following ICB therapy, supporting the rationale for targeting VEGF and CAFs in ICC management. This evidence concerns the gene VEGFA and intrahepatic cholangiocarcinoma.